Key result
Blocking the cardiac persistent sodium current (INa(P)) with agents like ranolazine or class I antiarrhythmics is a promising therapeutic approach for ischaemic arrhythmias and LQT3 syndrome.
Design
Review
Authors
Loading...
May inform ischemia-targeted Na channel modulation; leaves open whether kinetic heterogeneity reflects distinct channel populations.
The cardiac persistent sodium current (INa(P)) represents a promising therapeutic target for conditions such as LQT3 syndrome, ischaemic arrhythmias, and angina.
David A. Saint (2007) conducted a review in Cardiac arrhythmias, ischaemia, and LQT3 syndrome. Persistent sodium current (INa(P)) blockers was evaluated. Blocking the cardiac persistent sodium current (INa(P)) with agents like ranolazine or class I antiarrhythmics is a promising therapeutic approach for ischaemic arrhythmias and LQT3 syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: